Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinblastine +/- Bevacizumab in Pediatric Low Grade Glioma
NCT02840409Phase 2Active, not recruiting
- Sponsor
- SickKids
- Start
- Aug 2016
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in low-grade glioma (LGG) (2 arms), sponsored by SickKids. Primary endpoint: Response Rate at 6 months. Started Aug 2016; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT02840409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840409.